FY2026 · ended Jun 30, 2026 · Revenue $100,000, -75.0% YoY · Filed Aug 28, 2026
Ibio, Inc. (IBIO) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2026, which ended Jun 30, 2026, it reported revenue of $100,000 and a net loss of $33.0 million. Free cash flow was -$23.8 million. As of Jun 30, 2026 it held $88.0 million in cash and investments and $2.2 million in total debt.
Revenue
$100,000
-75.0% vs prior year
Net income
$-33.04M
-79.8% vs prior year
Operating cash flow
$-23.22M
-51.7% vs prior year
Free cash flow
$-23.80M
-55.3% vs prior year
EPS
$-0.32
+81.7% vs prior year
Dividend per share
None
Shares outstanding
64.31M
+227.2% vs prior year
Net cash
$85.84M
FY 2026
Operating margin
-35141.0%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- IBIO (Nasdaq)
- Fiscal year ends
- June 30
- Incorporated in
- DE
- Headquarters
- New York, NY
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1420720
- Former names
- iBio, Inc. (until Oct 19, 2026); iBioPharma, Inc. (until Aug 14, 2009); InB:Biotechnologies, Inc. (until Jul 17, 2008)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2026 Jun 30, 2026 |
FY 2025 Jun 30, 2025 |
FY 2024 Jun 30, 2024 |
FY 2023 Jun 30, 2023 |
FY 2022 Jun 30, 2022 |
|---|---|---|---|---|---|
| Revenue | $100,000 | $400,000 | $225,000 | $0 | $1.9M |
| Operating income | -$35.1M | -$18.6M | -$16.6M | -$29.3M | -$29.7M |
| Net income | -$33.0M | -$18.4M | -$24.9M | — | -$50.3M |
| Diluted EPS | -$0.32 | -$1.75 | -$6.50 | -$106.19 | -$5.78 |
| Operating cash flow | -$23.2M | -$15.3M | -$18.6M | -$30.4M | -$37.5M |
| Free cash flow | -$23.8M | -$15.3M | -$18.8M | -$36.2M | -$44.8M |
| Total assets | $99.1M | $23.2M | $28.7M | $41.2M | $99.4M |
| Total liabilities | $13.4M | $8.3M | $7.4M | $25.8M | $35.9M |
| Stockholders' equity | $85.7M | $14.9M | $21.3M | $15.4M | $63.5M |
| Cash and investments | $88.0M | $8.6M | $14.2M | $4.3M | $22.7M |
| Total debt | $2.2M | $2.7M | $3.5M | $4.1M | $3.7M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change, Bylaw or fiscal year change, Shareholder vote results
|
Oct 19, 2026 | Oct 14, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Oct 13, 2026 | Oct 13, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 14, 2026 | Sep 14, 2026 |
| ARS | Annual report to shareholders | Sep 4, 2026 | Jun 30, 2026 |
| 10-K | Annual report | Aug 28, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 28, 2026 | Aug 28, 2026 |
All 909 Ibio, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.